Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 8
Clinical trials of cetuximab in stage III colon cancer.
| | Trial (first author) | Phase | Protocol | Number enrolled | Results | HR (95% CI) | value |
| | NCCTG NO147 (Goldberg et al.) [33] |
III | FOLFOX 6 + cetuximab | 318 | 3-year DFS 62.3%
OS 79.1% |
DFS: 1.48 (1.08–2.03)
OS: 1.67 (1.00–2.80) |
0.02
0.07 | | FOLFOX 6 | 340 | 3-year DFS 70.3%
OS 86.1% |
| | NCCTG NO17 (Huang et al.) [34] |
III | FOLFIRI + cetuximab | 45 | 3-year DFS 80%
OS 90% |
DFS: 0.6 (0.3–1.1)
OS: 0.4 (0.1–1.0) |
0.09
0.04 | | FOLFIRI | 111 | 3-year DFS 65%
OS 83% |
|
|
DFS: disease-free survival, OS: overall survival.
|
